Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones (Q38604890)

4 September 2017

Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones (English)

1 reference

4 September 2017

0 references

1 reference

Antonios Douros

1

0 references

author name string

Katja Grabowski

series ordinal

2

1 reference

PubMed ID

26457865

4 September 2017

Ralf Stahlmann

series ordinal

3

1 reference

PubMed ID

26457865

4 September 2017

language of work or name

English

0 references

publication date

12 October 2015

1 reference

Expert Opinion on Drug Metabolism & Toxicology

4 September 2017

1 reference

4 September 2017

11

1 reference

4 September 2017

12

1 reference

4 September 2017

1849-1859

1 reference

The oxazolidinones: past, present, and future.

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Novel drugs against tuberculosis: a clinician's perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid pharmacokinetics in pediatric patients: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Use of linezolid in pediatrics: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Mechanism of action of the oxazolidinone antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid--a review of the first oxazolidinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Intrapulmonary pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Clinical relevance of linezolid-associated serotonin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Hematologic effects of linezolid: summary of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Severe drug-induced liver injury associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Hypoglycemia in patients treated with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

From an evolutionary perspective, all 'new' antimicrobial targets are old: time to think outside the box.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Clarithromycin significantly increases linezolid serum concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Linezolid and rifampin: Drug interaction contrary to expectations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

Potential drug interaction between warfarin and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1098617

10.1517/17425255.2015.1098617

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26457865